SCHEMBL13650554

SCHEMBL13650554

Nc1nc(NCC[C@H]2CC[C@H](N)CC2)c2c(n1)C(c1ccccc1)CCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 4/20 0.46
▸ HRH4 Q9H3N8 3/20 0.46
▸ HRH2 P25021 1/20 0.36
▸ PRKCQ Q04759 1/20 0.36
▸ APP P05067 3/20 0.35
▸ BCHE P06276 3/20 0.35
▸ ACHE P22303 3/20 0.35
▸ KMT5A Q9NQR1 1/20 0.34
▸ EEF2K O00418 1/20 0.33
▸ GBA1 P04062 1/20 0.32
▸ KDM1A O60341 2/20 0.31
▸ MAOA P21397 2/20 0.31
▸ MAOB P27338 2/20 0.31
▸ PSEN1 P49768 1/20 0.31
▸ PSEN2 P49810 1/20 0.31
▸ APH1B Q8WW43 1/20 0.31
▸ NCSTN Q92542 1/20 0.31
▸ APH1A Q96BI3 1/20 0.31
▸ PSENEN Q9NZ42 1/20 0.31
▸ TLR7 Q9NYK1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13650552 0.89 HRH3 (0.47) HRH3HRH4HRH2PRKCQAPP
SCHEMBL13650467 0.85 HRH4 (0.51) HRH3HRH4HRH2APPKDM1A
SCHEMBL13650647 0.83 HRH3 (0.51) HRH3HRH4HRH2APPBCHE
SCHEMBL13650547 0.82 HRH3 (0.48) HRH3HRH4HRH2ACHEEEF2K
SCHEMBL13650557 0.81 HRH4 (0.47) HRH3HRH4HRH2PRKCQAPP
SCHEMBL13650538 0.81 HRH4 (0.51) HRH3HRH4HRH2APP
SCHEMBL13650534 0.80 HRH3 (0.49) HRH3HRH4HRH2
SCHEMBL13650525 0.80 HRH3 (0.52) HRH3HRH4HRH2BCHEACHE
SCHEMBL13650528 0.80 HRH3 (0.52) HRH3HRH4HRH2ACHETLR7
SCHEMBL13650456 0.79 HRH3 (0.53) HRH3HRH4HRH2APPACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 — — US disclosed
WO-2009123967-A1 5,6,7,8-TETRAHYDROQUINAZOLIN-2-AMINE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4 RECEPTOR MODULATORS FOR THE TREATMENT OF ASTHMA ABBOTT LABORATORIES (US) 2009-10-08 — — WO disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP HRH3 3555/4885HRH4 3370/4885HRH2 2787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback